deltatrials
Recruiting PHASE4 INTERVENTIONAL 3-arm NCT07074444

Treatment of Clonorchiasis in Guangxi With Albendazole, Tribendimidine, and Praziquantel

Albendazole, Tribendimidine, and Praziquantel for Clonorchiasis in Guangxi: A Randomized Controlled Trial Comparing Efficacy and Safety

Sponsor: First Affiliated Hospital of Guangxi Medical University

Conditions Clonorchiasis
Interventions Albendazole Tribendimidine praziquantel
Updated 2 times since 2025 Last updated: Aug 13, 2025 Started: Jul 22, 2025 Primary completion: Nov 30, 2026 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Clonorchiasis and is currently actively recruiting participants. First Affiliated Hospital of Guangxi Medical University leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshotNot Yet Recruiting~Sep 2025 – present · 10 months · monthly snapshotRecruiting

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  2. Aug 2025 — Sep 2025 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Jul 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • First Affiliated Hospital of Guangxi Medical University
  • Guangxi Zhuang Autonomous Region Center for Disease Prevention and Control
  • People's Hospital of Guangxi Zhuang Autonomous Region
Data source: First Affiliated Hospital of Guangxi Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations